Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): A case-crossover study of Taiwan's National Health Insurance claims database and review of current evidence

BMC Cardiovascular Disorders

Volumn 12, Issue , 2012, Pages

  Shau, Wen Yi ^a   Chen, Hsi Chieh ^b   Chen, Shu Ting ^b   Chou, Hsu Wen ^b   Chang, Chia Hsuin ^b,c   Kuo, Chuei Wen ^d   Lai, Mei Shu ^b,c  

^a Center for Drug Evaluation   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d Bureau of National Health Insurance Taiwan   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACEMETACIN; ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLURBIPROFEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; INSULIN; KETOPROFEN; KETOROLAC; LOOP DIURETIC AGENT; MEFENAMIC ACID; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SULFONYLUREA; SULINDAC; PROSTAGLANDIN SYNTHASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MALE; NATIONAL HEALTH INSURANCE; OUTPATIENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; AGED; FACTUAL DATABASE; HEART INFARCTION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RISK; TAIWAN;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROSS-OVER STUDIES; CYCLOOXYGENASE INHIBITORS; DATABASES, FACTUAL; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; RISK FACTORS; TAIWAN;

EID: 84856449219     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-12-4     Document Type: Article

References (67)

1. Farkouh ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 2009, 103(9):1227-1237. 10.1016/j.amjcard.2009.01.014, 19406264.
2. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?. Lancet 2007, 370(9605):2138-2151. 10.1016/S0140-6736(07)61909-6, 18156036.
3. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006, 332(7553):1302-1308. 10.1136/bmj.332.7553.1302, 1473048, 16740558.
4. Hennekens CH, Borzak S. Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease. J Cardiovasc Pharmacol Ther 2008, 13(1):41-50. 10.1177/1074248407312990, 18287589.
5. Chen YF JP, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008, 12(11):1-278.
6. Friedewald VE, Bennett JS, Packer M, Roberts WC, Williams GW. The Editor's Roundtable: Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk. The American Journal of Cardiology 2008, 102(8):1046-1055. 10.1016/j.amjcard.2008.08.004, 18929707.
7. Hermann M. Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs. Curr Rheumatol Rep 2009, 11(1):31-35. 10.1007/s11926-009-0005-5, 19171109.
8. Vardeny O, Solomon SD. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk. Cardiol Clin 2008, 26(4):589-601. 10.1016/j.ccl.2008.06.004, 18929233.
9. Cheng JW. Use of Non-Aspirin Nonsteroidal Antiinflammatory Drugs and the Risk of Cardiovascular Events. Ann Pharmacother 2006, 40(10):1785-1796. 10.1345/aph.1H048, 16985093.
10. White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX, Weiner E, Verburg KM. Risk of Cardiovascular Events in Patients Receiving Celecoxib: A Meta-Analysis of Randomized Clinical Trials. The American Journal of Cardiology 2007, 99(1):91-98. 10.1016/j.amjcard.2006.07.069, 17196469.
11. McGettigan P, Henry D. Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2. JAMA 2006, 296(13):1633-1644. 10.1001/jama.296.13.jrv60011, 16968831.
12. Salpeter SR, Gregor P, Ormiston TM, Whitlock R, Raina P, Thabane L, Topol EJ. Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med 2006, 119(7):552-559. 10.1016/j.amjmed.2005.10.056, 16828623.
13. National Health Insurance in Taiwan 2010. , http://www.nhi.gov.tw/resource/Webdata/Attach_15634_1_National Health Insurance in Taiwan 2010.pdf
14. Waksman JC, Brody A, Phillips SD. Nonselective Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk: Are They Safe?. Ann Pharmacother 2007, 41(7):1163-1173. 10.1345/aph.1H341, 17609238.
15. Scott PA, Kingsley GH, Smith CM, Choy EH, Scott DL. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis 2007, 66(10):1296-1304. 10.1136/ard.2006.068650, 1994282, 17344246.
16. Joshi GP, Gertler R, Fricker R. Cardiovascular Thromboembolic Adverse Effects Associated with Cyclooxygenase-2 Selective Inhibitors and Nonselective Antiinflammatory Drugs. Anesthesia & Analgesia 2007, 105(6):1793-1804. 10.1213/01.ane.0000286229.05723.50, 22315331.
17. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbol EL, Sorensen R, Folke F, Buch P, Gadsboll N, Rasmussen S, Poulsen HE, Kober L, Madsen M, Torp-Pedersen C. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009, 169(2):141-149. 10.1001/archinternmed.2008.525, 19171810.
18. Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Kober L, Madsen M, Torp-Pedersen C. Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction. Circulation 2006, 113(25):2906-2913. 10.1161/CIRCULATIONAHA.106.616219, 16785336.
19. Roumie CL, Choma NN, Kaltenbach L, Mitchel EF, Arbogast PG, Griffin MR. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiology and Drug Safety 2009, 18(11):1053-1063. 10.1002/pds.1820, 19637402.
20. van Staa TP, Rietbrock S, Setakis E, Leufkens HG, Leufkens HGM. Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?. Journal of Internal Medicine 2008, 264(5):481-492. 10.1111/j.1365-2796.2008.01991.x, 18624902.
21. Hammad TA, Graham DJ, Staffa JA, Kornegay CJ, Pan GJD. Onset of acute myocardial infarction after use of non-steroidal anti-inflammatory drugs. Pharmacoepidemiology and Drug Safety 2008, 17(4):315-321. 10.1002/pds.1560, 18302311.
22. Solomon DH, Avorn J, Sturmer T, Glynn RJ, Mogun H, Schneeweiss S. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: High-risk subgroups and time course of risk. Arthritis & Rheumatism 2006, 54(5):1378-1389. 10.1002/art.21887, 22315615.
23. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, Rimm EB, Willett WC, Fuchs CS, Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, Rimm EB, Willett WC, Fuchs CS. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006, 113(12):1578-1587. 10.1161/CIRCULATIONAHA.105.595793, 16534006.
24. Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A, Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Archives of Internal Medicine 2003, 163(4):481-486. 10.1001/archinte.163.4.481, 12588209.
25. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR, Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002, 359(9301):118-123. 10.1016/S0140-6736(02)07370-1, 11809254.
26. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002, 360(9339):1071. 10.1016/S0140-6736(02)11131-7, 12383990.
27. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. Journal of the American College of Cardiology 2004, 43(6):985-990. 10.1016/j.jacc.2003.08.064, 15028354.
28. Fischer LM, Schlienger RG, Matter CM, Jick H, Meier CR. Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction. Pharmacotherapy 2005, 25(4):503-510. 10.1592/phco.25.4.503.61021, 15977911.
29. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.[Summary for patients in Ann Intern Med. 2005 Feb 1;142(3):I21; PMID: 15684199]. Annals of Internal Medicine 2005, 142(3):157-164.
30. Mangoni AA, Woodman RJ, Gaganis P, Gilbert AL, Knights KM. Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. British Journal of Clinical Pharmacology 2010, 69(6):689-700. 10.1111/j.1365-2125.2010.03627.x, 2883762, 20565461.
31. Garcia Rodriguez LA, Tacconelli S, Patrignani P, Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. Journal of the American College of Cardiology 2008, 52(20):1628-1636. 10.1016/j.jacc.2008.08.041, 18992652.
32. Helin-Salmivaara A, Virtanen A, Vesalainen R, Gronroos JM, Klaukka T, Idanpaan-Heikkila JE, Huupponen R. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case? control study from Finland. European Heart Journal 2006, 27(14):1657-1663. 10.1093/eurheartj/ehl053, 16731535.
33. Hawkey CJ, Hawkey GM, Everitt S, Skelly MM, Stack WA, Gray D. Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs. British Journal of Clinical Pharmacology 2006, 61(6):730-737. 10.1111/j.1365-2125.2006.02644.x, 1885122, 16722837.
34. Andersohn F, Suissa S, Garbe E, Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006, 113(16):1950-1957. 10.1161/CIRCULATIONAHA.105.602425, 16618816.
35. Levesque LE, Brophy JM, Zhang B, Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.[Summary for patients in Ann Intern Med. 2005 Apr 5;142(7):I45; PMID: 15809454]. Annals of Internal Medicine 2005, 142(7):481-489.
36. Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Friis S, Sorensen HT. Risk of Hospitalization for Myocardial Infarction Among Users of Rofecoxib, Celecoxib, and Other NSAIDs: A Population-Based Case-Control Study. Arch Intern Med 2005, 165(9):978-984. 10.1001/archinte.165.9.978, 15883235.
37. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005, 330(7504):1366. 10.1136/bmj.330.7504.1366, 558288, 15947398.
38. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. The Lancet 2005, 365(9458):475-481.
39. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004, 109(17):2068-2073. 10.1161/01.CIR.0000127578.21885.3E, 15096449.
40. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A. Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population. Circulation 2004, 109(24):3000-3006. 10.1161/01.CIR.0000132491.96623.04, 15197149.
41. Watson DJ, Rhodes T, Cai B, Guess HA. Lower Risk of Thromboembolic Cardiovascular Events With Naproxen Among Patients With Rheumatoid Arthritis. Arch Intern Med 2002, 162(10):1105-1110. 10.1001/archinte.162.10.1105, 12020179.
42. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal Anti-inflammatory Drug Use and Acute Myocardial Infarction. Arch Intern Med 2002, 162(10):1099-1104. 10.1001/archinte.162.10.1099, 12020178.
43. Schlienger RG, Jick H, Meier CR. Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol 2002, 54(3):327-332. 10.1046/j.1365-2125.2002.01637.x, 1874430, 12236854.
44. Garcia Rodriguez LA, Varas C, Patrono C. Differential Effects of Aspirin and Non-Aspirin Nonsteroidal Antiinflammatory Drugs in the Primary Prevention of Myocardial Infarction in Postmenopausal Women. Epidemiology 2000, 11(4):382-387. 10.1097/00001648-200007000-00004, 10874543.
45. Jick H, Kaye JA, Russmann S, Jick SS, Jick H, Kaye JA, Russmann S, Jick SS. Nonsteroidal antiinflammatory drugs and acute myocardial infarction in patients with no major risk factors. Pharmacotherapy 2006, 26(10):1379-1387. 10.1592/phco.26.10.1379, 16999647.
46. Brophy JM, Lévesque LE, Zhang B. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart 2007, 93(2):189-194. 1861373, 16849374.
47. van der Linden MW, van der Bij S, Welsing P, Kuipers EJ, Herings RMC. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Annals of the Rheumatic Diseases 2009, 68(5):668-673. 10.1136/ard.2007.087254, 18495734.
48. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E, . for the Cross Trial Safety Assessment Group Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis. Circulation 2008, 117(16):2104-2113. 10.1161/CIRCULATIONAHA.108.764530, 2965408, 18378608, for the Cross Trial Safety Assessment Group.
49. Delaney JA, Suissa S. The case-crossover study design in pharmacoepidemiology. Stat Methods Med Res 2009, 18(1):53-65. 10.1177/0962280208092346, 18765504.
50. Schneeweiss S, Sturmer T, Maclure M. Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf 1997, 6(Suppl 3):S51-59.
51. Maclure M. The Case-Crossover Design: A Method for Studying Transient Effects on the Risk of Acute Events. Am J Epidemiol 1991, 133(2):144-153.
52. The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD). , http://www.whocc.no/
53. Arora S, Wagner JG, Herbert M. Myth: Parenteral ketorolac provides more effective analgesia than oral ibuprofen. CJEM: The Journal of the Canadian Association of Emergency Physicians 2007, 9(1):30-32.
54. Kimmel SE, Berlin JA, Kinman JL, Hennessy S, Feldman H, Carson JL, Strom BL. Parenteral ketorolac and risk of myocardial infarction. Pharmacoepidemiology and Drug Safety 2002, 11(2):113-119. 10.1002/pds.670, 11998535.
55. Reinhart DJ. Minimising the adverse effects of ketorolac. Drug Saf 2000, 22(6):487-497. 10.2165/00002018-200022060-00007, 10877042.
56. Feldman HI, Kimmel SE. Parenteral ketorolac: The risk for acute renal failure. Annals of Internal Medicine 1997, 126(3):193.
57. Chang C-H, Shau W-Y, Kuo C-W, Chen S-T, Lai M-S. Increased Risk of Stroke Associated With Nonsteroidal Anti-Inflammatory Drugs: A Nationwide Case-Crossover Study. Stroke 2010, 41(9):1884-1890. 10.1161/STROKEAHA.110.585828, 20671253.
58. Department of Health, regulatory document.
59. Layton D, Hughes K, Harris S, Shakir SA, Layton D, Hughes K, Harris S, Shakir SAW. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. Rheumatology 2003, 42(11):1354-1364. 10.1093/rheumatology/keg401, 12867585.
60. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M, . Adenoma Prevention with Celecoxib Study I Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New England Journal of Medicine 2005, 352(11):1071-1080. 10.1056/NEJMoa050405, 15713944, Adenoma Prevention with Celecoxib Study I.
61. White WB, Faich G, Borer JS, Makuch RW. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. The American Journal of Cardiology 2003, 92(4):411-418. 10.1016/S0002-9149(03)00659-3, 12914871.
62. Garcia Rodriguez L, Gonzalez-Perez A. Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Medicine 2005, 3(1):17. 10.1186/1741-7015-3-17, 1310534, 16316472.
63. Fosbol EL, Gislason GH, Jacobsen S, Abildstrom SZ, Hansen ML, Schramm TK, Folke F, Sorensen R, Rasmussen JN, Kober L, Madsen M, Torp-Pedersen C. The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiology & Drug Safety 2008, 17(8):822-833. 10.1002/pds.1592, 22304573.
64. Vlahovic-Palcevski V, Wettermark B, Bergman U, Vlahovic-Palcevski V, Wettermark B, Bergman U. Quality of non-steroidal anti-inflammatory drug prescribing in Croatia (Rijeka) and Sweden (Stockholm). European Journal of Clinical Pharmacology 2002, 58(3):209-214. 10.1007/s00228-002-0449-2, 12107607.
65. Arellano FM, Yood MU, Wentworth CE, Oliveria SA, Rivero E, Verma A, Rothman KJ. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiology and Drug Safety 2006, 15(12):861-872. 10.1002/pds.1343, 17086563.
66. White WB. Defining the problem of treating the patient with hypertension and arthritis pain. American Journal of Medicine 2009, 122(5 Suppl):S3-9.
67. Lee C-H, Wang J-D, Chen P-C. Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiology and Drug Safety 2010, 19(7):708-714. 10.1002/pds.1966, 20582911.